$2.20
5.17% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US6033801068
Symbol
NERV
Reports
Quarter | Annual
Index
NASDAQ Composite
Sector
Health
Industry
Biotechnology

Minerva Neurosciences Inc Stock News

Neutral
GlobeNewsWire
●
11 days ago
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now
The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today